<SEC-DOCUMENT>0001628280-26-034834.txt : 20260514
<SEC-HEADER>0001628280-26-034834.hdr.sgml : 20260514
<ACCEPTANCE-DATETIME>20260514084856
ACCESSION NUMBER:		0001628280-26-034834
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20260514
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20260514
DATE AS OF CHANGE:		20260514

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Senti Biosciences Holdings, Inc.
		CENTRAL INDEX KEY:			0001854270
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				862437900
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40440
		FILM NUMBER:		26976053

	BUSINESS ADDRESS:	
		STREET 1:		2 CORPORATE DRIVE, FIRST FLOOR
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		(650) 239-2030

	MAIL ADDRESS:	
		STREET 1:		2 CORPORATE DRIVE, FIRST FLOOR
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Senti Biosciences, Inc.
		DATE OF NAME CHANGE:	20220711

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Senti Biosciences, Inc.\
		DATE OF NAME CHANGE:	20220615

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Dynamics Special Purpose Corp.
		DATE OF NAME CHANGE:	20210331
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>snti-20260514.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019de09b-83d7-7e92-bcf1-72a66e8098d1,g:6ccf2374-a3cc-4dfb-849f-ef3862725a63,d:0951ef7af374459b97ee91a480d3c06e-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>snti-20260514</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-22">0001854270</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-23">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="snti-20260514.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2026-05-14</xbrli:startDate><xbrli:endDate>2026-05-14</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i0951ef7af374459b97ee91a480d3c06e_1"></div><div style="min-height:31.5pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:4pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:115%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:115%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:115%">Washington, D.C. 20549</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:115%">___________________________________</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:115%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:115%">___________________________________</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:115%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:115%">Pursuant to Section 13 or 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:115%">of the Securities Exchange Act of 1934</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:115%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">May 14, 2026</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:115%">___________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:24pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">SENTI BIOSCIENCES HOLDINGS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">(Exact name of Registrant as specified in its charter)</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:115%">___________________________________</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"/><td style="width:31.726%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.726%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.730%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-40440</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">42-1912154</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">(State or other jurisdiction</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">of incorporation)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">(Commission</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">File Number)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">(IRS Employer</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Identification No.)</span></div></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">2 Corporate Drive, First Floor</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">South San Francisco</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">California</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">94080</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">(Address of principal executive offices including zip code)</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">650</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">239-2030</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">(Former name or former address, if changed since last report)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:115%">___________________________________</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:115%"> </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:2.845%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.955%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-13">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:43.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.170%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Trading</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Symbol</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">Name of each exchange</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:115%">on which registered</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock, par value $0.0001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">SNTI</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">The <ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">Nasdaq</ix:nonNumeric> Capital Market</span></div></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Emerging growth company <ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-20">&#9746;</ix:nonNumeric></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <ix:nonNumeric contextRef="c-1" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox" id="f-21">&#9746;</ix:nonNumeric></span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:4pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div></div></div><div id="i0951ef7af374459b97ee91a480d3c06e_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Item 2.02 Results of Operations and Financial Condition.</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">On <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-24">May&#160;14, 2026</ix:nonNumeric>, Senti Biosciences Holdings, Inc. (the &#8220;Company&#8221;) issued a press release announcing its financial results for the quarter ended March 31, 2026. A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form 8-K.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In accordance with General Instruction B.2. of Form 8-K, the information in this Item 2.02 of Form 8-K and Exhibit 99.1 attached hereto is furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Item 8.01. Other Events</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">On May 14, the Company issued a press release announcing certain clinical data and regulatory interactions related to its product SENTI-202. A copy of the press release is being furnished as Exhibit 99.2 to this Report on Form 8-K.</span></div><div><span><br/></span></div><div id="i0951ef7af374459b97ee91a480d3c06e_10"></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Item 9.01 Financial Statements and Exhibits.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">(d) Exhibits</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.939%"><tr><td style="width:1.0%"/><td style="width:13.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:83.417%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex991sntiq126earningsrelea.htm">Press Release, dated May 14, 2026</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">99.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex992sntifdameeting20260514.htm">Press Release, dated May 14, 2026</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i0951ef7af374459b97ee91a480d3c06e_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">SIGNATURES</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-top:12pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:5.425%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.054%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.942%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.866%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">SENTI BIOSCIENCES, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-25">May&#160;14, 2026</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">By:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Timothy Lu</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Name:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Timothy Lu, M.D., Ph.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Title:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Chief Executive Officer</span></td></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991sntiq126earningsrelea.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i8b56d6693a5746f1b56ea9f569d4ebbe_1"></div><div style="min-height:72pt;width:100%"><div><img alt="senti_logoxpra.jpg" src="senti_logoxpra.jpg" style="height:42px;margin-bottom:5pt;vertical-align:text-bottom;width:166px"></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:112%">Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-style:italic;font-weight:400;line-height:120%"> Secured strategic financing vehicle for up to $40 million </font></div><div style="margin-bottom:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-style:italic;font-weight:400;line-height:120%">Positive FDA feedback supports single-arm pivotal trial for potential registration of SENTI-202 in initial indication of Relapsed&#47;Refractory Acute Myeloid Leukemia (R&#47;R AML)</font></div><div style="margin-bottom:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-style:italic;font-weight:400;line-height:120%"> Continued operational streamlining contributed to substantially reduced quarterly net loss and cash burn</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SOUTH SAN FRANCISCO, Calif., May 14, 2026</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (GLOBE NEWSWIRE) -- Senti Biosciences Holdings, Inc. (Nasdaq&#58; SNTI) (Senti Bio), a clinical-stage </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the first quarter ended March 31, 2026, and provided recent business highlights.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;We entered 2026 with a clear focus on advancing SENTI-202 and extending our operational runway while positioning the company for its next phase of clinical development,&#8221; said Timothy Lu, M.D., Ph.D., Chief Executive Officer and Co-Founder of Senti Bio. &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Since the start of the year</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, we </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">have </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">made meaningful progress across each of these priorities, including </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">positive regulatory engagement with the FDA on SENTI-202 - a </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Regenerative Medicine Advanced Therapy (RMAT) </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">designated product - regarding the study design for the planned pivotal trial, execution of a strategic financing agreement that could provide up to $40 million in capital, and continued reductions in operating expenses and cash burn.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Dr. Lu added, &#8220;We believe the recent FDA </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">interactions and </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">feedback represent an important milestone for the program and further support the potential of SENTI-202 in relapsed&#47;refractory hematologic malignancies. We remain focused on advancing SENTI-202 efficiently toward the next stage of pivotal development in R&#47;R AML and </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">exploring future combinations with standard of care chemotherapy in newly diagnosed AML patients. We also aim to use our</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> differentiated gene circuit platform to create therapies for additional </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">in vivo</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> CAR therapies.&#8221;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Recent Business Highlights</font></div><div style="margin-bottom:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SENTI-202 Program Update</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Senti Bio concluded a Type B Initial Comprehensive Multidisciplinary RMAT meeting with FDA. Based on the positive outcome of this meeting, Senti Bio has finalized its pivotal clinical and chemistry, manufacturing and controls (CMC) strategy for SENTI-202, which includes a single-arm, multi-center pivotal trial to support registration in R&#47;R AML with SENTI-202 administered after LD chemotherapy.</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> The Company believes the FDA interaction supports continued advancement of SENTI-202 and provides important clarity around a potential registrational development strategy.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In addition, Senti announced that it identified a specific Donor X attribute that correlates with efficacy of SENTI-202, with 50% (7&#47;14) of the patients achieving a composite CR (cCR) when they received any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SENTI-202 doses manufactured from Donor X-characteristic derived NK cells in Cycle 1. The Donor X attribute is found in &#126;50% of adult donors, is independent of HLA or KIR matching, and will be used in all future SENTI-202 manufacturing, thus supporting SENTI-202&#8217;s allogeneic off-the-shelf usage. Senti Bio also announced that SENTI-202 continues to achieve durable MRD-negative responses in the full 22 patient Phase 1 trial that compares favorably with current FDA approved therapies for R&#47;R AML.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Additional details can be found on Senti Bio&#8217;s website (https&#58;&#47;&#47;investors.sentibio.com&#47;press-releases).</font></div><div style="margin-bottom:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Strategic Financing Agreement</font></div><div style="margin-bottom:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In April 2026, Senti Bio entered into a securities purchase agreement with an affiliate of Celadon Partners SPV 24, pursuant to which Senti Biosciences, Inc., the Company&#8217;s wholly owned subsidiary, may issue up to $40 million aggregate principal amount of senior secured convertible notes in up to two tranches.</font></div><div style="margin-bottom:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The financing includes&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12.03pt">An initial $10 million tranche, expected to close in May subject to specified closing conditions&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12.03pt">An additional tranche of up to $30 million, subject to investor election and additional conditions&#59; and </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12.03pt">Future potential contingent value rights tied to regulatory and commercial milestones for SENTI-202 that could provide up to an aggregate of $60 million in additional value to stockholders.</font></div><div style="margin-bottom:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company expects to use proceeds from the financing to support general corporate purposes and advance clinical and manufacturing activities for SENTI-202.</font></div><div style="margin-bottom:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Operational and Financial Restructuring Progress</font></div><div style="margin-bottom:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">During the first quarter, Senti Bio completed amendments to its Alameda lease and related GeneFab sublease arrangements, significantly reducing future lease obligations and streamlining operations.</font></div><div style="margin-bottom:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">These actions contributed to a $6.9 million gain from lease modification during the quarter and are expected to further reduce the Company&#8217;s ongoing operating expense profile.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">First Quarter 2026 Financial Results</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Cash Position&#58; Cash and cash equivalents were </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$8.9 million</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> as of March 31, 2026, compared to $16.4 million as of December 31, 2025.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Research and Development Expenses&#58; Research and development expenses were </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$5.3 million</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> for the first quarter of 2026, compared to $9.3 million for the same period in 2025. The decrease was primarily driven by lower external services and supplies costs.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">General and Administrative Expenses&#58; General and administrative expenses were </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$6.2&#160;million</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> for the first quarter of 2026, compared to $7.1 million for the same period in 2025. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The decrease was primarily driven by lower external services and supplies costs.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Net Loss&#58; Net loss was </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$4.2 million, or $0.14</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> per basic and diluted share, for the first quarter of 2026, compared to a net loss of $14.1 million, or $1.41 per basic and diluted share, for the first quarter of 2025. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Net loss for the three months ended March 31, 2026 included non-cash stock-based compensation expense of $1.3 million, offset by a non-recurring $6.9 million gain on lease modification.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Cash Burn&#58; Net cash used in operating activities was </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$7.5&#160;million</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> during the first quarter of 2026, compared to $14.1 million during the same period in 2025, reflecting continued operational discipline and restructuring actions.</font></div><div id="i8b56d6693a5746f1b56ea9f569d4ebbe_4"></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">About SENTI-202</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SENTI-202 is the first Logic Gated off-the-shelf CAR-NK cell therapy product candidate designed to selectively target and eliminate CD33 and&#47;or FLT3 expressing hematologic malignancies, such as AML and myelodysplastic syndrome (MDS), while sparing healthy bone marrow cells. SENTI-202 has three main components. First, SENTI-202 contains an OR GATE, which is an activating CAR that recognizes and kills CD33 and FLT3 expressing cells. By targeting either or both of these antigens, SENTI-202 is designed to effectively kill both leukemic blasts (that largely express CD33) and leukemic stem cells (that predominantly express FLT3), which constitute a difficult-to-eradicate reservoir of AML disease. Second, SENTI-202 contains a NOT GATE, which is an inhibitory CAR that is designed to recognize EMCN selectively expressed on healthy hematopoietic stem and progenitor cells and protect those healthy cells from being killed even if they express CD33 and&#47;or FLT3, thus potentially widening the therapeutic window. Third, SENTI-202 contains calibrated-release IL-15, which is designed to significantly increase cell persistence, expansion and activity of both the CAR-NK cells and host immune cells. The NK cells used to construct SENTI-202 are sourced from selected healthy adult donors, manufactured, cryopreserved and available off-the-shelf for use as needed. Senti Bio is currently enrolling adult patients with R&#47;R CD33 and&#47;or FLT3 expressing heme malignancies in a Phase 1 clinical trial for SENTI-202, which can be a potential first-in-class allogeneic treatment for AML&#47;MDS patients.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) and Regenerative Medicine Advanced Therapy (RMAT) designation to SENTI-202 for the treatment of relapsed&#47;refractory hematologic malignancies including AML.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">About Senti Bio</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Senti Bio is a clinical stage biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases. To achieve this, Senti Bio is leveraging its synthetic biology platform to engineer Gene Circuits into new medicines with enhanced precision and control. These Gene Circuits are designed to precisely kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and&#47;or to be controllable even after administration. The Company&#8217;s wholly-owned pipeline comprises cell therapies engineered with Gene Circuits to target challenging liquid and solid tumor indications. Senti Bio&#8217;s Gene Circuits have been shown preclinically to work in both NK and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">T cells. Senti Bio has also preclinically demonstrated the potential breadth of Gene Circuits in other modalities and diseases outside of oncology, and continues to advance these capabilities through partnerships.</font></div><div id="i8b56d6693a5746f1b56ea9f569d4ebbe_7"></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This press release and document contain certain statements that are not historical facts and are considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally are identified by the words &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;predict,&#8221; &#8220;continue,&#8221; &#8220;ongoing,&#8221; &#8220;project,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;strategy,&#8221; &#8220;future,&#8221; &#8220;opportunity,&#8221; &#8220;plan,&#8221; &#8220;may,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;will be,&#8221; &#8220;will continue,&#8221; &#8220;will likely result,&#8221; &#8220;forecast,&#8221; &#8220;seek,&#8221; &#8220;target&#8221; and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements are predictions, projections, and other statements about future events that are based on current expectations of Senti Bio&#8217;s management and assumptions, whether or not identified in this document, and, as a result, are subject to risks and uncertainties. Forward-looking statements include, but are not limited to, expectations regarding Senti Bio&#8217;s future results. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as, a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Senti Bio. Many factors could cause actual future results to differ materially from the forward-looking statements in this document, including but not limited to&#58; (i) changes in domestic and foreign business, market, financial, political and legal conditions, (ii) changes in the competitive and highly regulated industries in which Senti Bio operates, variations in operating performance across competitors, changes in laws and regulations affecting Senti Bio&#8217;s business, (iii) the ability to implement business plans, forecasts and other expectations, (iv) the risk of downturns and a changing regulatory landscape in Senti Bio&#8217;s highly competitive industry, (v) risks relating to the uncertainty of any projected financial information with respect to Senti Bio, (vi) risks related to uncertainty in the timing or results of Senti Bio&#8217;s , clinical studies, patient enrollment, and GMP manufacturing startup activities, (vii) Senti Bio&#8217;s dependence on third parties in connection with clinical studies, and GMP manufacturing activities, (viii) risks related to delays and other impacts from macroeconomic and geopolitical events, increasing rates of inflation and rising interest rates on business operations, (ix) risks related to the timing and utilization of the grant from CIRM, and (x) the success of any future research and development efforts by Senti Bio. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the &#8220;Risk Factors&#8221; section of Senti Bio&#8217;s most recent annual report filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;), and other documents filed by Senti Bio from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements in this document. There may be additional risks that Senti Bio does not presently know, or that Senti Bio currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements in this document. Forward-looking statements speak only as of the date they are made. Senti Bio anticipates that subsequent events and developments may cause Senti Bio&#8217;s assessments to change. Except as required by law, Senti Bio assumes no obligation to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">update publicly any forward-looking statements, whether as a result of new information, future events, or otherwise.</font></div><div id="i8b56d6693a5746f1b56ea9f569d4ebbe_10"></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Availability of Other Information About Senti Biosciences Holdings, Inc.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For more information, please visit the Senti Bio website at www.sentibio.com or follow Senti Bio on X (&#64;SentiBio) (https&#58;&#47;&#47;x.com&#47;sentibio) and LinkedIn (Senti Biosciences) (https&#58;&#47;&#47;www.linkedin.com&#47;company&#47;senti-biosciences). Investors and others should note that we communicate with our investors and the public using our company website (www.sentibio.com), including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X (https&#58;&#47;&#47;x.com&#47;sentibio) and LinkedIn (https&#58;&#47;&#47;www.linkedin.com&#47;company&#47;senti-biosciences). The information that we post on our website or on X (https&#58;&#47;&#47;x.com&#47;sentibio) or LinkedIn (https&#58;&#47;&#47;www.linkedin.com&#47;company&#47;senti-biosciences) could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.</font></div><div id="i8b56d6693a5746f1b56ea9f569d4ebbe_13"></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Investor Contact&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">JTC Team, LLC</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Jenene Thomas</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(908) 824-0775</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SNTI&#64;jtcir.com</font></div><div><font><br></font></div><div id="i8b56d6693a5746f1b56ea9f569d4ebbe_16"></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#404040;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SENTI BIOSCIENCES HOLDINGS, INC.</font></div><div style="text-align:center"><font style="color:#404040;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Unaudited Selected Consolidated Balance Sheet Data</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#404040;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(In thousands)</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:70.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.761%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2026</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</font></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8,935&#160;</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16,420&#160;</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Total assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">38,241&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">51,223&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Total liabilities</font></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">35,676&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">45,634&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Accumulated deficit</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(362,793)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(358,572)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</font></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2,565&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5,589&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#404040;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:112%">SENTI BIOSCIENCES HOLDINGS, INC.</font></div><div style="text-align:center"><font style="color:#404040;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss</font></div><div style="text-align:center"><font style="color:#404040;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:112%">(In thousands, except share and per share amounts)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.626%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2026</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</font></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Revenue - related party</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16&#160;</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Research and development (including related party costs of $282 and $4,070 for the three months ended March 31, 2026 and 2025, respectively)</font></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5,281&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9,281&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">General and administrative</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6,233&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7,116&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Gain on lease modification</font></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(6,882)</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4,632&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16,397&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Loss from operations</font></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(4,616)</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(16,397)</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Other income&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Interest income</font></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">101&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">394&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">GeneFab sublease income - related party</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">80&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1,713&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Other income, net</font></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">214&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">178&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Total other income, net</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">395&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2,285&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Net loss</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(4,221)</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(14,112)</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Comprehensive loss</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(4,221)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(14,112)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Basic and diluted net loss per share</font></td><td style="background-color:#dbdbdb;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#dbdbdb;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(0.14)</font></td><td style="background-color:#dbdbdb;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#dbdbdb;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1.41)</font></td><td style="background-color:#dbdbdb;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Basic and diluted weighted-average number of shares used in computing net loss per share</font></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">30,971,573&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10,012,908&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>ex992sntifdameeting20260514.htm
<DESCRIPTION>EX-99.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="ia635cf004cb1401994930ff41d1015c2_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 99.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed&#47;Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Following a Type B meeting with FDA, Senti Bio plans to proceed with a single-arm multi-center registrational trial for SENTI-202, building off the strong Phase 1 clinical results demonstrating deep and durable MRD-negative complete remissions</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">To further optimize SENTI-202 efficacy, the selection criteria for donors for all future manufacturing will include the &#8220;Donor X&#8221; phenotype</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Phase 1 clinical trial patients receiving SENTI-202 from Donor X-derived NK cells achieved a 50% composite CR (cCR) rate</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SOUTH SAN FRANCISCO, Calif. &#8212; May 14, 2026</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#8212; Senti Biosciences Holdings, Inc. (Nasdaq&#58; SNTI) (&#8220;Senti Bio&#8221; or the &#8220;Company&#8221;), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced the successful completion of a Type B Initial Comprehensive Multidisciplinary Regenerative Medicine Advanced Therapy (RMAT) meeting with the U.S. Food and Drug Administration (FDA) regarding SENTI-202, the Company&#8217;s first-in-class Logic Gated off-the-shelf CAR-NK cell therapy for relapsed&#47;refractory acute myeloid leukemia (R&#47;R AML) and updated Phase 1 clinical data.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Following the RMAT meeting, the Company has finalized its pivotal clinical and chemistry, manufacturing and controls (CMC) strategy for SENTI-202. The Company plans to implement a single-arm, multi-center pivotal trial intended to support potential SENTI-202 registration in patients with R&#47;R AML. This study is expected to evaluate SENTI-202 administered following lymphodepletion (LD) chemotherapy in a patient population consistent with the Phase 1 trial population.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In addition to the positive RMAT meeting, after conducting exploratory efficacy covariate analysis of the Phase 1 trial results, Senti has identified a specific Donor X attribute that correlates with efficacy of SENTI-202, with 50% (7&#47;14) of the patients achieving a cCR when they received any SENTI-202 doses manufactured from Donor X-characteristic-derived NK cells in Cycle 1 versus 12.5% (1&#47;8) achieving a cCR when they received SENTI-202 manufactured from non-Donor X NK cells (see Table below). As a result of this discovery, all future SENTI-202 manufacturing, including for pivotal study use, will use Donor X material. The Donor X attribute is found in &#126;50% of adult donors, and published literature supports increased NK cell cytotoxicity in donors with this phenotype. The Donor X NK phenotype is independent of HLA or KIR matching, thus supporting SENTI-202&#8217;s allogeneic off-the-shelf usage. Retrospective analysis of preclinical MV4-11 NSG mouse model data confirmed increased activity and survival with Donor X product (see Figure below). </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Senti Bio also announced that SENTI-202 continues to exhibit durable MRD-negative responses in the full 22 patient Phase 1 trial, which compares favorably with current FDA approved therapies for R&#47;R AML. At RP2D, across all patients receiving a mix of Donor X and non-Donor X material, an ORR of 44% and cCR of 37.5% was observed with 100% of CRs being MRD negative. The complete remissions continue to be durable, with all the CR&#47;CRh responders who were in remission as of the data-cut </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">supporting the oral presentation at the 2025 ASH annual meeting continuing to maintain remission with an additional 7 months of follow up, the longest duration being 21+ months. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;This positive FDA RMAT meeting marks a transformational moment for Senti Bio and significantly advances our path toward potential registration of SENTI-202,&#8221; said Tim Lu, M.D., Ph.D., Chief Executive Officer and Co-Founder of Senti Bio. &#8220;This news, combined with the compelling clinical responses observed to date that led to refinements in our donor selection strategy, positions us to advance SENTI-202 toward a potential registrational study in relapsed&#47;refractory AML. We believe this milestone further validates both our Gene Circuit platform and the differentiated therapeutic potential of Logic Gated cell therapies.&#8221;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">FDA previously granted RMAT designation to SENTI-202. This program is intended to facilitate the expedited development and review of regenerative medicine therapies addressing serious or life-threatening diseases.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;The FDA feedback provides important clarity around our registrational development strategy and further supports our conviction in the SENTI-202 program,&#8221; said Kanya Rajangam, M.D., Ph.D., Chief Medical Officer of Senti Bio. &#8220;The excellent clinical activity observed thus far, including MRD-negative durable complete remissions alongside a favorable safety profile, gives us confidence as we transition toward later-stage development. We are focused on rapidly implementing the pivotal study while also exploring potential expansion opportunities in newly diagnosed AML and pediatric AML.  Since the filing of our IND, Senti has focused on donor selection to minimize variability. We are in a strong position as we prepare for our clinical trials with the identification of a donor phenotype that correlates with increased activity and continues to support SENTI-202&#8217;s allogeneic manufacturing.&#8221;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Relapsed&#47;refractory AML remains an aggressive hematologic malignancy with limited therapeutic options and poor long-term survival outcomes. Senti Bio believes SENTI-202&#8217;s differentiated mechanism, off-the-shelf availability, and encouraging early clinical profile position the program as a potentially important next-generation treatment option for AML patients.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Table&#58; Phase 1 SENTI-202-101 Trial R&#47;R AML Patient Efficacy Data Based on Donor Phenotype</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:112%">All Patients<br>(N&#61;22)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Any Donor X in Cycle 1</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:112%">No Donor X in Cycle 1</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">ORR (Overall Response Rate)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:112%">8&#47;14 (57%)</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">2&#47;8 (25%)</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">cCR</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:112%">7&#47;14 (50%)</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">1&#47;8 (12.5%)</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><img alt="picture2.gif" src="picture2.gif" style="height:207px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.570%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Vehicle</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Non-engineered NK (NK3)</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:112%">SENTI-202 (NK3)</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Non-engineered NK (NK4)</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:112%">SENTI-202 (NK4)</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Median Survival (d)</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:112%">56.0</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:112%">64.0</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:112%">86.0</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:112%">112.0</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Not Reached</font></div></td></tr><tr><td colspan="18" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Figure&#58; Retrospective analysis of preclinical MV4-11 NSG mouse model data confirms increased activity and survival with SENTI-202 made from Donor X product. Donor X characteristic was confirmed post-hoc</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div><div id="ia635cf004cb1401994930ff41d1015c2_4"></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">About SENTI-202</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">SENTI-202 is a first-in-class Logic Gated off-the-shelf CAR-NK cell therapy designed to selectively target and eliminate CD33 and&#47;or FLT3 expressing hematologic malignancies, including AML and myelodysplastic syndrome (MDS), while sparing healthy bone marrow cells. SENTI-202 incorporates multiple engineered Gene Circuits, including OR GATE and NOT GATE logic systems and calibrated-release IL-15, to improve tumor specificity, persistence, and therapeutic activity.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">SENTI-202 has received Regenerative Medicine Advanced Therapy (RMAT) designation and Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">About the Phase 1 Study</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">The multinational, multicenter dose-finding study of SENTI-202 (NCT06325748) (https&#58;&#47;&#47;clinicaltrials.gov&#47;study&#47;NCT06325748&#63;cond&#61;NCT06325748&#38;rank&#61;1) comprised an initial dose finding using a modified &#34;3+3&#34; study design to determine the maximum tolerated dose (MTD) and&#47;or recommended phase two dose (RP2D) of SENTI-202 when administered after lymphodepleting chemotherapy (Part 1) followed by disease-specific expansion cohorts at the RP2D (Part 2).</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">The primary objectives were to evaluate safety, determine the MTD and RP2D, and assess efficacy in expansion cohorts using ELN 2022 consensus criteria for AML, with key secondary objectives including measurable residual disease assessment, pharmacokinetics, and pharmacodynamics using CyTOF on serial bone marrow samples. For more information visit clinicaltrials.gov (https&#58;&#47;&#47;clinicaltrials.gov&#47;)</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">About Senti Bio</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Senti Bio is a clinical stage biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases. To achieve this, Senti Bio is leveraging its synthetic biology platform to engineer Gene Circuits into new medicines with enhanced precision and control. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">These Gene Circuits are designed to precisely kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and&#47;or to be controllable even after administration. The Company&#8217;s wholly-owned pipeline comprises cell therapies engineered with Gene Circuits to target challenging liquid and solid tumor indications. Senti Bio&#8217;s Gene Circuits have been shown preclinically to work in both NK and T cells. Senti Bio has also preclinically demonstrated the potential breadth of Gene Circuits in other modalities and diseases outside of oncology, and continues to advance these capabilities through partnerships.</font></div><div id="ia635cf004cb1401994930ff41d1015c2_7"></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This press release and document contain certain statements that are not historical facts and are considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally are identified by the words &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;predict,&#8221; &#8220;continue,&#8221; &#8220;ongoing,&#8221; &#8220;project,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;strategy,&#8221; &#8220;future,&#8221; &#8220;opportunity,&#8221; &#8220;plan,&#8221; &#8220;may,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;will be,&#8221; &#8220;will continue,&#8221; &#8220;will likely result,&#8221; &#8220;forecast,&#8221; &#8220;seek,&#8221; &#8220;target&#8221; and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements are predictions, projections, and other statements about future events that are based on current expectations of Senti Bio&#8217;s management and assumptions, whether or not identified in this document, and, as a result, are subject to risks and uncertainties. Forward-looking statements include, but are not limited to, expectations regarding Senti Bio&#8217;s future results. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as, a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Senti Bio. Many factors could cause actual future results to differ materially from the forward-looking statements in this document, including but not limited to&#58; (i) changes in domestic and foreign business, market, financial, political and legal conditions, (ii) changes in the competitive and highly regulated industries in which Senti Bio operates, variations in operating performance across competitors, changes in laws and regulations affecting Senti Bio&#8217;s business, (iii) the ability to implement business plans, forecasts and other expectations, (iv) the risk of downturns and a changing regulatory landscape in Senti Bio&#8217;s highly competitive industry, (v) risks relating to the uncertainty of any projected financial information with respect to Senti Bio, (vi) risks related to uncertainty in the timing or results of Senti Bio&#8217;s , clinical studies, patient enrollment, and GMP manufacturing startup activities, (vii) Senti Bio&#8217;s dependence on third parties in connection with clinical studies, and GMP manufacturing activities, (viii) risks related to delays and other impacts from macroeconomic and geopolitical events, increasing rates of inflation and rising interest rates on business operations, (ix) risks related to the timing and utilization of the grant from CIRM, and (x) the success of any future research and development efforts by Senti Bio. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the &#8220;Risk Factors&#8221; section of Senti Bio&#8217;s most recent annual report filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;), and other documents filed by Senti Bio from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements in this document. There may be additional risks that Senti Bio does not presently know, or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that Senti Bio currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements in this document. Forward-looking statements speak only as of the date they are made. Senti Bio anticipates that subsequent events and developments may cause Senti Bio&#8217;s assessments to change. Except as required by law, Senti Bio assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events, or otherwise.</font></div><div id="ia635cf004cb1401994930ff41d1015c2_10"></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Availability of Other Information About Senti Biosciences Holdings, Inc.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For more information, please visit the Senti Bio website at www.sentibio.com or follow Senti Bio on X (&#64;SentiBio) (https&#58;&#47;&#47;x.com&#47;sentibio) and LinkedIn (Senti Biosciences) (https&#58;&#47;&#47;www.linkedin.com&#47;company&#47;senti-biosciences). Investors and others should note that we communicate with our investors and the public using our company website (www.sentibio.com), including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X (https&#58;&#47;&#47;x.com&#47;sentibio) and LinkedIn (https&#58;&#47;&#47;www.linkedin.com&#47;company&#47;senti-biosciences). The information that we post on our website or on X (https&#58;&#47;&#47;x.com&#47;sentibio) or LinkedIn (https&#58;&#47;&#47;www.linkedin.com&#47;company&#47;senti-biosciences) could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.</font></div><div id="ia635cf004cb1401994930ff41d1015c2_13"></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Investor Contact&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">JTC Team, LLC</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Jenene Thomas</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(908) 824-0775</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SNTI&#64;jtcir.com</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>snti-20260514.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019de09b-83d7-7e92-bcf1-72a66e8098d1,g:6ccf2374-a3cc-4dfb-849f-ef3862725a63-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:snti="http://www.sentibio.com/20260514" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.sentibio.com/20260514">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="snti-20260514_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="snti-20260514_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.sentibio.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>snti-20260514_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019de09b-83d7-7e92-bcf1-72a66e8098d1,g:6ccf2374-a3cc-4dfb-849f-ef3862725a63-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_SolicitingMaterial_019de09b-83d8-7f64-8882-ff9bc94b07ab_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_019de09b-83d8-7783-89bd-cf8af066064f_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_019de09b-83d8-738c-bd68-5c710e465176_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_019de09b-83d8-7a06-894e-e04c0f643a6b_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_019de09b-83d8-7546-b4ae-053111a5e1ea_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_019de09b-83d8-720e-865b-56e65701a06a_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_019de09b-83d8-7fd8-a8ed-591798efb45b_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_019de09b-83d8-784f-9b5e-d123f129be1a_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_019de09b-83d8-761d-9cae-51761e56471a_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_019de09b-83d8-7deb-a482-2e66f73b73f2_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_019de09b-83d8-78e0-8769-2783a356bf39_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_019de09b-83d8-781b-98b0-757cbe3af764_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_019de09b-83d8-7ed7-b398-af964c24f9d3_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_019de09b-83d8-7231-a8c9-4f1239e7abf6_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_019de09b-83d8-7b7b-9abe-0c707ae51117_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_019de09b-83d8-7a9f-b791-82434ce71439_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_019de09b-83d8-7764-80c1-dc3cac42a77a_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_019de09b-83d8-7581-ad94-197d277c6768_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_019de09b-83d8-73bf-953f-9bb6ab10c419_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_019de09b-83d8-70b0-9ca8-5a64ffa491ba_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_019de09b-83d8-7956-8a68-c3a9236704c3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_019de09b-83d8-7ff2-8570-41285cb7a3d2_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_019de09b-83d8-715d-b65b-c38e75af75b9_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>snti-20260514_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019de09b-83d7-7e92-bcf1-72a66e8098d1,g:6ccf2374-a3cc-4dfb-849f-ef3862725a63-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.sentibio.com/role/Cover" xlink:type="simple" xlink:href="snti-20260514.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.sentibio.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_019de09b-83d8-7131-bd3a-61e99ebeccb8" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_019de09b-83d8-79b0-b006-b5298dd97171" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019de09b-83d8-7131-bd3a-61e99ebeccb8" xlink:to="loc_dei_DocumentType_019de09b-83d8-79b0-b006-b5298dd97171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_019de09b-83d8-7cee-80c8-96dc80cbaaf0" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019de09b-83d8-7131-bd3a-61e99ebeccb8" xlink:to="loc_dei_DocumentPeriodEndDate_019de09b-83d8-7cee-80c8-96dc80cbaaf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_019de09b-83d8-7723-af46-0da53ad8a803" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019de09b-83d8-7131-bd3a-61e99ebeccb8" xlink:to="loc_dei_EntityRegistrantName_019de09b-83d8-7723-af46-0da53ad8a803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_019de09b-83d8-7446-a3cc-b9dc65e39d61" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019de09b-83d8-7131-bd3a-61e99ebeccb8" xlink:to="loc_dei_EntityIncorporationStateCountryCode_019de09b-83d8-7446-a3cc-b9dc65e39d61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_019de09b-83d8-7ef0-a9be-a241487e2ff0" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019de09b-83d8-7131-bd3a-61e99ebeccb8" xlink:to="loc_dei_EntityFileNumber_019de09b-83d8-7ef0-a9be-a241487e2ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_019de09b-83d8-7e8d-a968-a48671d70f17" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019de09b-83d8-7131-bd3a-61e99ebeccb8" xlink:to="loc_dei_EntityTaxIdentificationNumber_019de09b-83d8-7e8d-a968-a48671d70f17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_019de09b-83d8-788b-8990-fb4cabc150cb" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019de09b-83d8-7131-bd3a-61e99ebeccb8" xlink:to="loc_dei_EntityAddressAddressLine1_019de09b-83d8-788b-8990-fb4cabc150cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_019de09b-83d8-74f6-bc3e-5473c5bc2dab" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019de09b-83d8-7131-bd3a-61e99ebeccb8" xlink:to="loc_dei_EntityAddressCityOrTown_019de09b-83d8-74f6-bc3e-5473c5bc2dab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_019de09b-83d8-7a57-b485-3eff68b3144e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019de09b-83d8-7131-bd3a-61e99ebeccb8" xlink:to="loc_dei_EntityAddressStateOrProvince_019de09b-83d8-7a57-b485-3eff68b3144e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_019de09b-83d8-7980-bb4a-c0344a3810f3" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019de09b-83d8-7131-bd3a-61e99ebeccb8" xlink:to="loc_dei_EntityAddressPostalZipCode_019de09b-83d8-7980-bb4a-c0344a3810f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_019de09b-83d8-7347-8fad-669ac3016e59" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019de09b-83d8-7131-bd3a-61e99ebeccb8" xlink:to="loc_dei_CityAreaCode_019de09b-83d8-7347-8fad-669ac3016e59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_019de09b-83d8-7935-8546-60b4633c148e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019de09b-83d8-7131-bd3a-61e99ebeccb8" xlink:to="loc_dei_LocalPhoneNumber_019de09b-83d8-7935-8546-60b4633c148e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_019de09b-83d8-776c-bf7b-20f1ea49e628" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019de09b-83d8-7131-bd3a-61e99ebeccb8" xlink:to="loc_dei_WrittenCommunications_019de09b-83d8-776c-bf7b-20f1ea49e628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_019de09b-83d8-7ed2-9bd8-a5ea8a5c21af" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019de09b-83d8-7131-bd3a-61e99ebeccb8" xlink:to="loc_dei_SolicitingMaterial_019de09b-83d8-7ed2-9bd8-a5ea8a5c21af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_019de09b-83d8-7d0d-b280-3e2ca088e2f6" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019de09b-83d8-7131-bd3a-61e99ebeccb8" xlink:to="loc_dei_PreCommencementTenderOffer_019de09b-83d8-7d0d-b280-3e2ca088e2f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_019de09b-83d8-7f48-939f-85113017167e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019de09b-83d8-7131-bd3a-61e99ebeccb8" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_019de09b-83d8-7f48-939f-85113017167e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_019de09b-83d8-70a1-b7af-21096e49dcc6" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019de09b-83d8-7131-bd3a-61e99ebeccb8" xlink:to="loc_dei_Security12bTitle_019de09b-83d8-70a1-b7af-21096e49dcc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_019de09b-83d8-7b8e-9daf-ea1a26bb3804" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019de09b-83d8-7131-bd3a-61e99ebeccb8" xlink:to="loc_dei_TradingSymbol_019de09b-83d8-7b8e-9daf-ea1a26bb3804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_019de09b-83d8-7953-96c2-c02a6d4a1be3" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019de09b-83d8-7131-bd3a-61e99ebeccb8" xlink:to="loc_dei_SecurityExchangeName_019de09b-83d8-7953-96c2-c02a6d4a1be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_019de09b-83d8-7bf8-b811-d4b4a51fa0cc" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019de09b-83d8-7131-bd3a-61e99ebeccb8" xlink:to="loc_dei_EntityEmergingGrowthCompany_019de09b-83d8-7bf8-b811-d4b4a51fa0cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_019de09b-83d8-7f19-9501-94aa6eb59b2f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019de09b-83d8-7131-bd3a-61e99ebeccb8" xlink:to="loc_dei_EntityExTransitionPeriod_019de09b-83d8-7f19-9501-94aa6eb59b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_019de09b-83d8-707e-bb74-27703089b412" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019de09b-83d8-7131-bd3a-61e99ebeccb8" xlink:to="loc_dei_EntityCentralIndexKey_019de09b-83d8-707e-bb74-27703089b412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_019de09b-83d8-73a1-9c95-8b51235a543a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019de09b-83d8-7131-bd3a-61e99ebeccb8" xlink:to="loc_dei_AmendmentFlag_019de09b-83d8-73a1-9c95-8b51235a543a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>picture2.gif
<TEXT>
begin 644 picture2.gif
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MB"H*=*B>*\E)XD! !AF1 )+V)J(%<$4:@0E%BOCA10*@$$$"%!VZCXO\3!F
M"8&>^=*.G':*PG*+;FK"IA&H&&D I.X)XP%$<NH/B;=. <"-A1)D#[$BFJ!H
MLY7"VJFK R6 ZXBX^GE1/ %X@*:(#2 $IH@^IA?C=XNNJHTX35*+$ %-[A-=
M N3JY"@("_!SJ) &C1L OP(TR:A*CGHJD+_\/J1"I0@Q*>A;+#XI4(@/"X">
MQ>19O&<&"FA,$ $"#)"! >*((8Z#'M-Y00;H'1J!BS<F:H# T5F<K,U[A@Q
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M!"PZFO\*%O4!56T@;):3JX@TZE-H">J;<%S+ '"7(B\A0$1#! "8A(2D#R3
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MC)Z$I'12;&5S%0<?Y2%9)PTQ1!^0X7,CR8 9!]!;ZT2!W<+;-I91S%N'2C(
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M4U@)DD.8*@U,&N56!))5I"E$2G;>[A;BD^0CDJ/E 4VRGL<C ("'8][,WP6
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M_>5Y-N<?@9).#!8=Y:9U0D<0._(./), !$<;@;9I2U>%U38G._-MHK4!O<(
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M>+2B2H*+Z_0X@MF'="*6M",0>#DBPMF= N$ D;.+L[.?:B$.X., +U80!N
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MJ[_SN[_^>[_]&\#TV[]&0, $7, #G,#UV[]0 +[B^\!F(0#&*PX(_X"^<WH
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M "=F !H@SQJP /Y49^-YD,EA !-0#QHP 0]] ?2P !KP#K@(THVQSR.A OC
MR>H, )_LS<K:$,7_?,P8D<B+[!8[?09'$-='< :DT--Q#=<^;1 "$!OSD #I
MP !3<(MFX@ 'F0'(T0X)8"9^ZP#]L  .(-$,L  )<,I<G1>BXSJ<$TLOG<T=
ML<THK=)6,LHMK1 B3<7G#!'E?-I>H0V!, .<[-HS8  S -NS'0@T JP 2-05
MG X.,%")#3*\W0#&A7[FH0'?> "$G0!!6]EGH0 \DP$/ #H.W-?CV0^'LP#X
MDGJMA '\W-DF/=9EW;?"_!!SB@':VA%LK=I=(09BH VI(P#:H U?X-[PS35"
M_3'I8 'Z4*P@<(O]@%Y&)P#JX "(O0#Z8#$,0 \238N_X;#,G19G.YX6F "_
M[3#6]X$"Z5"XL8H![W!##H+-(R$&GIW2 FTE2SC:"2$/&&#:,JW*ZET6]WTG
M]@ "DZ@/2SBSS<K."+"$D8U>$]#;\A ;3<;2#XX6"H+52&X!ZO#1]F!%"& "
M[;  %K#!&+V/_3"=(M$&_NS>O@S**_W1ZW;0Y\T1Z7T8$E*T#P ;M_$ AC,
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MF2IX*R-MS%&!J 10Z&<HZGHS3P#S'++PH0P1LE"; <QACD.P-A31H0&0(A$
M 3*HCBL-0# @J0586X  !=1Y)[FDO&(@@@6&,D =>1* H*<%('B@G0/LJ<>>
MV8H<\"*[HJ2R2JY8H^< +8\T$*(,-M@@'A@7T."!!>)18( ,&&! @@-0B RN
MJ@0BR/^@S+QJT*.)-F#*RB@+S FE!"]2(9 S!MI(  = <ZX??<3)  +^"'C
M'DG[>PZ"X>;)  %)#0C/GGX@D.<! WZ#H!]['E@QU> ,<&#3"S2]@!]-Y;&0
M >HVB%&YGR:81X$C(5A G@86T!$ !@Y8TP0/.#/@'0D2\&H!!\0!D=4)$NBI
MG0"MY,Y/<;LCH)\#)@ ! PS\VBHC8?OBU8(:W]F U79 P!>%".A#RYT'Z+RL
MW:XPY<@ ?),=5SL.QCDM)]4XS.""B"^X8 YUUI$X8P(N%* ?,@]0@-@,%EB@
MG2/[:>\=$'3,0(,)#E@ @03>(_F"!*S= (1E':#7/0>BW7;_ P;XT6!+! X
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M0IT+<WB'=8$*!* (&_42*](&<3BB!S2HQ2.TQO,W'\6*A;(@KN36CZ@\\+B
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MP !M%PYD /! G82$,F?2K&GS)LZ<,RM4T.GS)]"@0H<2+6KTIH!^4U!L:,!
M0$F<&1: V #"@ 00**8@J&D _P6#HT:U/9#41B:!! RT_=0F(LR7H0108+@@
M]B[>O'H3BJ$00@7> 00(1,WP ( " P8R:!M<,H."F00D2,@PP!QAP0080#!P
M0,-@ @_$*21, *MEA1+D/1 PCT#"TPQ2/Y"W.",  8,3BC/P14%+ ((SX#;0
M[@*!U J)[\Z= ;;SD@SH0=]K'4"%$M>W<^_N':> !Q! 1(BPX6G."_T8JAA@
M@)Z$R#0O8(#PW::V&4?.QE:+6Z<*(H@0EU#@8(""7?<IN"!0%.2@(&!B);#
M 1M $)5U8MPEA@,(8"B4 B,Q>!1/(YIX(HK";;:!"1%X8 ((P>$TP'\J1.B5
M!V&9*"M (/O)]  ])/T4X( :!O4 70FFN*1W?87 9%"3V6/ ?U#:))I1 A!G
MI4_9_W'Y)9A"?9$."B"\0R4#'C2$UP4HV&>B-B&<P9]"#MBCS8TWJ:#-%W#E
MZ=,\&-05)J%%J5#!@X4J>M^'BR94HJ.1?JG  0? IMMFI.5E  8ZCBB ?G02
MT,Y:0[Y%X)%T52,IJS0Y^6>KL<HJE)>SVOK=BOH8P,\$(%27ESSUH3C#G#\Z
M@)Y/1*(*E#@'/D6  J%).^VT\PA0Y:W<.9@MM]WNU).WX1XUP$/EH8"">=CB
M9"U@N@D *Z="CJA-CR%$]8!:;"5[JE!BS!4!!AL(O($%%A!L<,$'$[SP C&)
M:YTV?L'Z,,6%UEHQQCK-0T_ ![23 $H_"5"I;@ELP%)-]/^]^:F<HOJ7+  "
M+ON3.!N45UZ+-^N\\\T!1)! HQD7M:W0%8M1@  %N&.D=>[@HZ\823--$Z1%
M6YV0E@;TDP $"-BC9$X")/ !".) P!0("6!K0(XGYN=C;$%.7).R4_N4-3^*
M*9:WW@;(<T'?>MN<P-5&O5IXN"%0L#@%%3QI70@=H,-6"1UH=]/%B&<\S]8'
M6# %"" L0)%._-@\Q0.?=03:<H;9X^:)*A#KLCWJTJU"GU_,S5T[/P>MN4Y$
MYX4I=,038.VU,EUK/ '+8T@CM E!CYM@"F"[/%328\^7M5A#=>WO#*J@>.,5
M=-#!XP!H8[<8^O+EODQ3FY]# 13_=. .3E4#7[$ !D0$ 3VV)@&[U60J5-E
M!BRP  *\8P.$Z<<"-/ .\GB*060Q"UJ"!!2WP,5$!_C9_H+B)  !93,)2  ]
M^"$ ?J0#A6IY  /L<2G;&" ![5@ /2"0-Q7*) ,0Z <$6N+#?CQ+ C]$5FXN
M\+<@)B0#K&$ /W)C  C 9@#\8( YYF& 7Z$H<I?+@>4 @(\24* $3QIC#DJ
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M;;-#"ZG@AY, =7!$'R1</7,2L?39B)0>Y0 'Q.%1C]9$;!:@4@88\  '@$8
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M@038E35<.^4P7>O W#B@'?ZCHD(,XC__9R(5-AW!2&QPZ9!H-J"F!Y! /##
M5X1,I0&V1(@XB)G?[WC1'070;E<59\:S=L"L(1 #6O,X$S>"49YN_2^W" "!
M!K1# QOXQA0.X$^CM*F2"\I/L?K#39O8*'>[V\Y%=US/-?(&I)F%@F1!"N<Y
M=Y8F_;-,_T#P0]#02!OF: <]OH  JV!4'A9P;P+4P0!UO ,Y$XHB Q9PF-S"
M< %3E0FE(/#( SQ@*B XB08LU8X-*%%TAU2; !: XA3!\WP="*<VT!%/^Q4
MNCDH0@C$BL=P>E<FYL2?_4HP3^R0%\JV$H=H$#!+!' 1+U^IX(($T 8,)@1(
M##BS3#CXA6%S_^>BQIY)Q!(E/5*VISTC);=-OC A!JR( 0X@=7L-<Q$:+2 "
M[4C(:W.:@'0T3S<-A, %.JWJE:AE _JHC*9&9I\2#Z ?)MC B5UR,L4@]3P*
M68 \GEN"$K"C!#DPTCK+",<"..Z=Z'@2R<N(OQQ40+PJ8/GC?BQLS+WUV[(2
M@P&F,%"P;+DH@CW10V-SK)[+9+\,\J2:0Z@AO^@) '^:VWL-HMH$K(A"[TB
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M.7XC>+$C.H[3.:YC.\ZC.]*C/=8C/MKC/>YC/N;C.?$C>%T7+3H* 0R,<%D
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M0)E&!BR& \CIDHA!K.(H6HR$-FI?>F8AD'*JMN:KOAI%01+? 6" 1A80!D2
M!N32_*7#R6!+!M27E5!J!EUJT=UJF*RG";3GOEXLQA;%F+Q?3'F$3H@A4UB
M/&3 !,B87W89EY@#?\ZJI6)+GNJ.>MI,GV8LS=8LHO+6@72K3RC  W1::R &
M<MB$6C9LG:(%$6FC^F1JH9 HW]G_K-/6K!B836?HYG;$:(H( (?:*?9QZ8%&
M@,.@B!<^K=B65T%: '(00%A:AY1RB<-66S]DH^15E*)\Z<_XC_](P-WF+0/@
M[=[J+=_^K=\&;C%MD7V.K>&JZ *0 P88C)99!\I:B<IBJ=$B@,O&3+WNZ0;X
MS+EL+N=VKN=^+NB&;GV$[>&6;I&JW< T[G;J'Y,\J]': X'.)0TF .B$#@:
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M$XK91) &,++O^80!\#  G VA*2R[+@G6PFMLN"'W"G&7_M<9(\-P(H]RMV1
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M AO[87P0E $&!@(82#"YX0 *"95] FV908'-"_\;%F"TMV!#9H\@4:3+( ;
MA;UI43"8 (+ SP<;3"0@8  $!A0FWI&&$&^#.-95D2=7OIQY<^?/H4>7[E'O
M!@\02!J55Q"T 74@/!?]S/U".@P@"A-584"#A@WT0&X(+W0 A(P"-NQ#L0#!
M=O#IN@**H,<<  V$?GB;8BL%@H*(  $.P("T!-CK+1T&89+@M[U\(N"DUCP
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M?;9S 9M1+MKHH\,58(((\#(!A4;%4,!47H?%59R-&QJ5UGY03&"_KD8>=ED
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MP%[J\0X&: "$U&O( \Z410=X+7; R< 1$["!*:0#+Z9A@%D\9 %QW/%X(#
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&CP$0$  [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>senti_logoxpra.jpg
<TEXT>
begin 644 senti_logoxpra.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  J *8# 2(  A$! Q$!_\0
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M1VR",=,4DGQT\<_#3Q%X<G^(/P>T;P]HFI:A'8+J.FW$<LL,KG"D 9Z<GMD
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MFU8:F/%&K-J8C$'E_9\ECLSN.[[W7CITIB/,OC]#';_M/? &*)%BB2YNU5$
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(@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>May 14, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 14,  2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SENTI BIOSCIENCES HOLDINGS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">42-1912154<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2 Corporate Drive, First Floor<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">239-2030<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SNTI<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001854270<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="snti-20260514.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sentibio.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="snti-20260514.htm">snti-20260514.htm</File>
    <File>snti-20260514.xsd</File>
    <File>snti-20260514_lab.xml</File>
    <File>snti-20260514_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="25">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "snti-20260514.htm": {
   "nsprefix": "snti",
   "nsuri": "http://www.sentibio.com/20260514",
   "dts": {
    "inline": {
     "local": [
      "snti-20260514.htm"
     ]
    },
    "schema": {
     "local": [
      "snti-20260514.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "snti-20260514_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "snti-20260514_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 25
   },
   "report": {
    "R1": {
     "role": "http://www.sentibio.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "snti-20260514.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "snti-20260514.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.sentibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.sentibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.sentibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.sentibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.sentibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.sentibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.sentibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.sentibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.sentibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.sentibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.sentibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Ex Transition Period",
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.sentibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.sentibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.sentibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.sentibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.sentibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.sentibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.sentibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.sentibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.sentibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.sentibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.sentibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.sentibio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001628280-26-034834-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-26-034834-xbrl.zip
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M/537>&&F-$'/AB'>5#3R'1#Z)%ZUQ<[G>DT<6$(C,AGR!.1]ZF>Z=8X;!?Z
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M41***&:7W_Z7M3H.+A"G:#'!RMI^G4F8ZSRY0RQM[+><^H8*:QW4&./56/\
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M%K(<3OT08+86*X !6*;@%NDGC!2H6E2&].2L8I\*"VW5[0-$HBC)0BITR$J
MLZQ]/L!JII'&U+X6>S=(]H/!6G.![TLUSIB.32CXC&L!!]+&0*CF[:IO2NTA
M ?U>OP09KI3&[%&4#DHQ+:#1C9.C@TW2 (,(2!MHX&LT&@+<Z.(C,W^ KOQZ
M=*1EX7(#%;S"&D#".>%FCE(&>."19;NQ"[,YEBSC?AT+RG),%39Z7P\>ZI*<
MSW3#^KW3HM"['[/"N"AL#%\P,8JFSEGAX,N;K&$/D&KZ XP61(&8-P]@IYY3
MECX^?!_Q@9U !581/ 85 6R8MEKLU!8A7"C GB@.IXIU<33N/C T;7N4PJ&F
M;)!-KLQ$N^GI(U$-(JF\%DKEHOK0MV8VB(L+&I7IZ%)/O*.D*AU=*F@4C6VL
M0EV"E<O:RDRH0CIVBH(4?NT)NSLMR4G%Z@X_7N+_>K&G;JHFNZ9KLD=R),C7
M061'$L/:!<L8T6C!*3P-KS(D\LVZ0Q"W=/$ L/U7*K58BI4/?TO2 &=*94,%
MX_J<5H7RRC1BJ"?@:/$0]DHP-M1* Q?86$77J#5(\8(RO;.,<IV8>N[$U$LK
MP,S3*;7R4K-2F50\$9!A1;Y@>5H((L#3'L>TL&#4)8O!--@M!6MTI%(++.PL
MCK& $^Y4H4M"J#PC1_=#F2)$[<ZX?,1[TJP&+IE*!T.0D+KC8BA'CP\K;%<R
MK'"B(IR*4CM3ZIJ:T!)  =7455<_7F&;N'92K-] >,\F6&L' X@OHC_C[$S:
M#T,Y'ZJ$P3)@V9!J17,\SBK=T,@'PJ'.0P,?W\"GL!9*6M,E9V::Z>%XNIZ\
MM7U@^V4O\UZ? Y=LK.9N&WPI9(6 XM*:++-;F\=S;CV^!>D=@@&0K]$IKF&U
MX!T[-N6X_H1.6>@:[DWH:2"MO=A.2S+MW=GT0/,UU49/?XD>N'23V6LUGTU_
M;TH#9U=16)\__;6N.YS^%N,.V':4S*PNP-8/YGR/[>GAS-9MO_CT][IR=&;G
M5-><@KL]<P-._)K^+N SEX&BG - [!^=^6[1A:!QYWZ]"-STHR^O!57&8D'B
MS&$52&,>SWP?"W$]_9TV)>R79#Y(8&X>9:XCEJ!F@1F)U)J9%<)6Y*(]!!2)
MQA+XK)[^6Y$Y"V0+Q%Y@54!M@@7U[&0QH>,BYN&X&X<9TM(?<,]:<Q1O(>^@
MO+ML0ST[N<+VM&J:-+7$Q9&8F:$$3KX=R$=B!:S$8&0V, ;#V 33\*@%1B1Y
M@G$/(\MHLYK++>ITN"%O90&#\%J++NS])8F7T)"L.^!C\EX.ZZ4YQ#%4JLM[
MG?+Y\G%WL\<T #,S8Q\@@S1JS*18&F+J^VE6MY&U!ZC0GV3RF(!$W&N#O=$-
MA4$H' MWTQ4]W(8O-:(P'1=.\CX?CGAG@Y23CRT<"I0"3K!A"#\5R(52H!Q,
MDCZUC]V(?/N(:E05> 4<HJ=-A4D=97(*M&GHAFP,-%,"',Y%A0;HC-BP(_$#
M3DN(J2-2^R;$*%DKN9YXI:-)!=*ILR]X*OZ I_7$1(6>&1E+CLC4Z%9:J4_.
M?6PZ7ER>ZBIR7+V,6=REV13*UD@'__+NC[MH;9JD\X !DE^9]'1F;D-N,JWM
MZ'Y/!8)"[31;#F053EJTXX4QGA9="U@W&V$,_*[0A+,M)3X0<+&ERX$'E)]@
M)^N"PTH8IY @#B.:V"8B8DX/*=4$PJ8Z;4U^"CW!&P[@F3-X$?Z"_B]9FV;B
MJ7TFQ04+^_'Y.#:I+7JZ[EG0<?2Y?)A# XX&9\,#&>HD)Q9;+H+25&;45S$E
M\DGTQP6Q6.1^7/!&KX>2!HG( U</:,-T47"];]Q6H=\*%O=B,*:IJ7)VNP:V
M19 ;Z(*)O@'/TU)-.W^ZIPAWD$LX"N<B!1O)7II@+4.",QE3Y _C6 ,C+K.]
MX'-DZ4%:N!2?82@CP232 -G6<L-<D>\40S5 X$@+=FZ"CLAF(IU]_O)MJM.)
MIABGHT+JF78(6YQ]DAU* 81$XY1DY)&38D@3*#TTMJ2>Q#"SK?E;F'[T//!X
M\-=)D5B M,AX)ED0(%UCMD0%AET'0N7,J"668V,J1#,TB0;@"4C3A*[I7NI9
MYM0U#P+>7):S?:%A!TGT=LY6"Z@C]9@ ._PG"XGAKQ1QU3L_/+WXHN&R<:O)
M/4Y=5^@2&1*5F3Q<4##=[]/ (] \!2E[I86CT+TP/I@Q5H>@V 6QB.)/W XY
M1JAO1)W]GTJ9MA%IFB/.WYAD#HF5M68YNPPW@EXC9(%!@,$P-Y(]:V4(:]!=
M(%N?Z*6R4>&&?.:;-I@K,=-3>1BF-)")^OVPK<?+!Q!3\+O@PN">,C?F4 6!
M)&N1;9B=7!X?F@UL%JTTJSEBLWX1PD8%R8#T*/V9/1Z6RPP2Z=.[8HRI-;'M
MON1$9G1L!D\M F"A-[2D*0MZ^"':$C-RQD7-<;&$ J4S18+&,V!N)>\\U1O7
MPU\R 'E*:"HS<UPQ !JJL9-9W(7.O"R!E,WV(D<QL(<H@H"B."4XS![^R4Y\
MART+DIU?&WLQMHSMF3F@VM/%N>.E:3F9[VB@A5,OQ%\IL7&.S )WQP1M?=I9
MA@ +#>@H:V34!%Y'4A>C!'<587=1I$D75'LQ<D[6'6&HT)^(JZS#I#]*F#2E
M,9'@^P#^75\[+HNY(W<?"UXATCWF30J6CU-V9HG?2=*-93RO]_*!KV5K5#*,
M>:!3YMK>!5A\)0"=%NS J>S?@C?)5#?H"1(0%"]*XR**1SK\>0/64F("AE:P
MV*%2(-[&XW%I>!220A_,434N^B\A^Q=JXFYGG[[$-^?,GTAUFPV@LHOJK/29
M#*^%=QH6WKUCP;Q@)=R83W?),%O4M;DP^X!:K[!0'?!D!F+E)D)L32:<+J1%
M^I@<NB -==B)C )\T8HLW4VI!N([\_(<O,3F5+.Q7-/PVRSXL,X<)];)T[(R
MQL$QP(9D]9I@A-'$A5;TDX-_4C[U7E/)&#)..?Z-G_4I0,W2J&R<JH!#Z' B
M"II](Z/3X$SH[16_I_#2F!+$L:&"QV']R3",1G/1A[,(':'AB58I(,DB!Z7:
M4GN&&YY\R\8DZF'&&:2T9S+ F=E4.$R='12#>6-\AQ#<'6%J/Z--QV05/,F+
M1&Z](5L_=B-!Y"=W 2LA2Q%]*N.<ZY)^4]V$-IF-L$[!-%9Z3@IM(<:TL8VQ
MF1," ]BA'F36@*MBZ Z+A%"#$:4R_=:@AZ5!'J^5VI742E92T7OHP$@NC05[
M2>4Q:TR^[//_Y^J070D>..SL[/"U]R)"3"-?#57 9Y.<+[N7C=W&SB;;:75J
MC>WMK5?>#+XWC]3_GXDK(Y1\RUGB#V35[CUOR%WBW:EK3^AI/:'[7NUI*+#3
MP'^>05Y292+[=/KU\O#T^/SP^)+]]O7LZ/3\\R58Y^>'BZWSU][X[R$'8Q U
MX:4M_0613V55I!\_<9^B_I=#(1)VQ!/^E&]<?>[3;9RB5:'2&&/ZB]\5.V^;
M"16_98P7@2V C4I48;IG_[(/5O+(YY,]&=+#Z:;'O(![=[>^L]5$/DJ UA//
M/MBP6)U8[)?$F_UMNU'?VNDL_+E1;R[\[:YEFZWZ]M;NHY:]^[?V;O=9-MM]
MV(9^(?AJ& ,68S"-?WW7?I?+06J^VVNP)ME<=KT[+FV-;O'B65J?QKI&^),9
M<HW[.(#D<M8VFA'__2=:F<,7A_B4SO^C44'QG<@_$@%@4^8RB)]M2O5Z^,_^
M'<?%/MUG/NR]5C ==N%4L&G,WW=8H^T2-=J#LYH::]QW"0P-5F5@O'^F0^]/
M&ZF5..V.L]LV+=?/<V[\:<GSWR$\[F6S:0&TIMA5H]AFU^FT&E4DV:55A)E;
M\!94Q!6]]PN3OK-:(3MK:[FSSN6JZA!:>\=I=9I+$MI\E#ZK!)QZY$(3;+6P
ML]5T6JWVZV%GE>U!S>R^S+J"'L7Q<PY<<9IJ;SG=[>[C5$N%;)X5Q4X'L-/N
MO!YV5EF]'[AN&IB2;VP"<&7R@VCYC7:WY6SOMC?7*KYZJ-G:<;:V6Z^"FM77
M[\57M9BR3HK])),?1-VWG*WN(V,?:VW_[/:]L[6S^\K*_A?*RCU9ZGZ=\/_!
M$_[-UAM-^-/&\X3_H<)&K'@ZXW]9:E_.WORDBS!QVDLDAG ;-K[A$.3*'K24
M^\>^8&IIH"' >M <=E'K3_3VSR7K QXG*%ZVJ@ XM=[0W/J(LH)NZWDR]>WG
M*2O8>I;-=A;__)1E!;MO++%Z12,_OR@:4'U<'E#]3)GV!T?]*PJR!^;@[S_F
MCP&K'R=O?X%M3JE@M:P#&!NB9]RW=0YT]7*@5<Q_KE/V:W*=>UJ*+K7VJTBS
M3Q34U\36J!ZU%5_"F[^.-"YUY3Q+*/HUUWAIG5]PW<KOX%CJS21/9!(L&-6Q
MD4\@*AD+^A50](J7UDZ+;GO?<1K;C25>*8,WV;=8T- 9FN@^Y16O?+RRM;-L
ML<@ZF/Q"R-E]7>0\J9+9K9Z2(1@O?C/A#Y))[CJM]BL6)*USR7<A9]MI+NTT
M52^;7'$)L/!U;S](0GFCZ^SL+%&NL-;_;\$!?0'^MVF;4(7B;HR^U)6K7.RF
MRU_4C%/\/7;*=P2EJL,F':?;;CU.258CLOB$MLU*(+39==J[VU7$Z"JG9<[H
MA;PX!C*?U_H]%M!*D.(&")=F=VG;J!IRY0FMIM5 IA8L%</F*MLL>K@C#B +
MQ#IX_V!7N5U1=)[:&=\:HS^(?]QLK"/D%45->_?M=U95F^4Q/G[">SAW6P?(
M-.O?5[RSHO'8G64[^->1\I<2TLYVL[I]U2L0*7N+]DK1_'18*![7'?KVU&*K
M^8IJ<6VQW"FGMG?>O,5225XWX?$GX?A5"J:V=Y=M%EW'QBN,SI;3VJDD0E<Y
M-'XN$N87>__6-=\K6O.]T7%:K6;%(L3K#H4UM2Y(:'2<9G/YTIV*:8(W9&66
M^\&7T@G?;X54!@H/Y[+E#EU1+EM2)[PE^WE-K2M'K<OJA"IX!RL;'ZTD0WSB
ML7GELR=QMHZ'@1)29OF0D.\P*=I (Y["?-'J2HHE3UU14=&H-SO?8SS>=>:W
MX^RLZ?6MT&NSWODNW_PYZ'65O9U91:$O%UZ-P_[P19AA2B^<47VM-F*6QOK%
MX?@:SI0*U>]7+H^,XB[-N-4AY7;#V=UN.EO;C\Q95T0(/T]T_@WCM=EP&LV6
ML]M8-LOW,GA]COF0U9CT^$M/>1/X8Y@$_L?_!U!+ P04    "  ;1JY<V,&Y
M'!8:  "!=P  'P   &5X.3DR<VYT:69D86UE971I;F<R,#(V,#4Q-"YH=&WM
M75MW&S>2?M]?@;5/,M09DA$IR;(M3\[12';BC25[9<W,[M,>L!LD$74W.HUN
M4IQ?OU\5@+[PXLBQ8\N)\^!0W6QTH5"7KPJHXK-YF2;?/YLK&7__'\_^<S 0
MYR:J4I65(BJ4+%4L*JNSF?A7K.R-& S\M\Y,OBKT;%Z*\?[XD?B7*6[T0KK[
MI2X3]7T8Y]EW[N]GW_%+GDU,O/K^6:P70L=_>Z#EHX.C:+J_?QA-1H?[HR=/
M#I\<[$^GAZ-XM#\ZBL;_-WJ 1_%U]XPM5XGZVX-49X.YHO<_/1[GY<E2Q^7\
MZ6A__YL'_+WOGTU-5N)E!1YV'S?&*-5M.9")GF5/>28/W$/A=F024SQ]N,__
MG="=P52F.ED]_<L9GIH4^B]]*S,[L*K04_<%J_^MGHZ((/YSZ2G$\XG.5*!X
M-"8RG]_.]427XLF3X;A+X[LHC<!157QB4M_BI5K\71L;:95%RHH?31)#*JPX
MS3)3\:4WQNI2+Y1X<7XJKBY.K\6%4B6)CLG$E9II6Q:RU":3B3C#.W2$#S*+
MQ=G%F7A+]]1L)::F$&^?7UZ_'$"NA*8G$YE;%7_[\/#XY$I-"QF5IEB)TXM7
M?7&:&(R_U.5<O$QS4Y023'D^G6+L:,6#GU>%G.A$EROQCSS&.RR14\Y5ZRTU
M-6\*,RMDNB$Q[RE-O]<:\4A/=8FO1YU5.]RZ:B],DI@E+8 4UZM<B;^+U*\(
M<PSKU!?UTHH\P=M%B0^%B13TGK\D!6E_H@:R2$5:):4>N.F)HKND9:'Q;V?Y
M^F)2:9838:939CH>H!5[,Y=6B9&( N<+93&V%;%*3>9&Q==BI7)>Q9A6,5'B
MXNI\D*F99#F+3)HGJE1X.-76@@S[!UFY:R.F50%^%<+DI4XQ6$M<E9?OON.H
M2E1$:P![K4&\EKP(L<E,8?FC3+ N55D52J0RJZ90H*IP4H [.HN2*E8\UK</
M'X_'^R?G]*SX'_YK="+RN<I,"0'Z@W!W0_B<Z.:0*A!H(4Z1T@MB4,/S:6%2
MX?DRB$') @IR^9.(5))8(:.Y5G1%BJ/];U@PR1@J<78E>M'9U9X@Z_:A[/NY
MLJ6>KCZU[7_]C^L?Q=O32_'BZO3R[.7;L]=]02-/ARPOH_&)N) K,3KL,Q0(
M,_E]:-R^HC4ANQU57[S,HJ'H74H;RU^^?7CT&-_&ZNZ)GI?Z^MD@]UCKEE*<
M85%EMO(W]_I8ZR! $$ Y4V*B3:FB>8;)PI%%[ONP80N5F)S$*:.UG*E,.:/)
MPL/FC:[1NPJ9:]#L )>&*,(4YX56I83#^X&^=*:+J )H@+$NH=LI;("));DZ
MYX9C9Q.J"'.WTRH)1I)>9Z:-(WB9P5>3(\;M0D'!+5G4"[+OL0;S<DR-7@J_
M[>FEVRK6$9@O3N.%Y)==,\TKT2-_O]=U+T3(/X9OA^*%,;'SQ44UP[/ ;K7C
M$#UXH3WR);*(.RKGK%N+ZZ/C$]@S7=AR / 7)=):\<K,="1^8)@*%S/ (P,[
M5\E4G)U>#;Q^>LXZ;%&TX431P D95=#7=(6UTK%(5'4#IR(Q,8<["&[L\20J
M1A'QI@O#93F\[SK^:TB!>,[8S2]E9Q4$IHP5@+?'V+$34+TPL+L-%XA%T9P<
M<EG 0W4=#M\$-86!T>P!]^T)NQ7X#4FRZM?6R$23+'-LTH8E_2XN"20YJZYQ
M+8M)+PS4(B>,*'+H:<;BWQCX-IHAV%E[ Y;EEA00:=J"[BI>"7Q0MSG\KWN!
M6LBDPG1:XTHO[JK 5Z8UGY-5FL]-K()N]EZ=[S'?3!!6T" #%: XKQ)O- !S
M:#Q<K=4LR*)W9/67OU!Q?(FIQ['FZ8*K-,,\!!==X9136G&P)*XBMCQ8#= F
M6:4#3L+]A01GL"X2LKL"^\@6;C+.@]  BDG:=4P?IYI]N\5*XW,4@("0)1Z<
MD.$HYQ(!LRG(O%",P4M3$X"WM>P:WR.<T#MFL1H=[@5Z:JESB,)A=P (L82)
MIF^L/#HA>J 9C9S%QN*UC;J1M+4Q2S279.JP(%C1:!/"0-S.5E%"S%BHPE96
MC,;#(] X8AH?[]V%I(:<34(RDPT"W^JW]JQ2XIJA_026=[DW%*>8O%\)QQ6L
M%KDD [)@4%I@=MO;6"H<I"5*R:@$>^ TMK*J[X O/M4+F4I&SHFS.YO+JPE)
M5[!>8-.W#T?C1R>T?N108Z+3@>T^V[>\FB0:/@A.A."X9%*]Y2$V4U;%-IP7
MT:HTI;F%8RU9Z3UP][J-%]?PNTL<GJ_O$'T:5BXG4Y<QWWY\=4H YJ>75S0Y
M+)VSY5A73TO'V=;^%>PUY/$AY%U_6EE G"'P (PWZ0$K8UN= "-J)W#QS\/!
M:"0NW_X@4D-\3F'JG(<D98433\E_U+R0-!S-GQAHJV*A84@="\)T@81(QYW$
MO- SXFH0F2_3RC61MTRLZ2 XV))&N,EAZJQ2[ &53QIM#8BA-3F\@V)M)G,"
M )B(\;AV(QUS!S68ZVCN@"H>%5.Y,#3JRG$^JF#-\!"E<V0._B\<NO0@E52K
MXQ9/2W'U9GP.+8@@(BQ*VV(J*5)]2P)3:QG6O&T<@BZ2.HG75U?TW</#;QQX
M..,_#X[)-"UAG\T$W%^$9 7E_^C^V96%<-#;P!\1^./T9TO6H&8Q<7BB G.]
MI98.06)0GNW9U=PS&C84>CHW8@GG3BRO1Q2R]C D\P-@RTTA#7+63F,Z-V>R
MI^Q'0/-&8C,\-3%E:=*G^\TC<F)- F-U]UQH^]]Y$4;.H>B#"33S9L#N]:E,
MEG)E'WRT_.L'Y&9W3N(^*7;+P)($0*<2LHX6BN @'-2;;D"YC\3IVQ])]2M\
M)T1/7AKY>0-U (25'>ER8MF )#Q[#!.;E7,6.X<R$:@X\$XI4F6=R>#7.\T8
MC_[JG_E2#:@/S!F.YQO)Y\#-5!8W!"F [3-+(7-(6*:&(PF..QI33 X(4R*8
M)[,2ME"Z6!><K0JR9_#*9HE@M15%=&*'#M8+J00K$51>ZU2\JOKB8G@^[,,6
M\__. *JFXOFM@HT@^E\39@2FY<2X&;P@U$%IP&E#Y%"T9YZI)9 'K-H$#(J;
MF(#L'/ %"U0KR^H=1&TW(6$4SSJGD[@+"(LQ5LJ&&X)'$V=4TLHUAK"M+X+]
MH;0%/>SYU7)@GE]R!\=J:,8ROCTZ9P?S+_;XE&ASP BB!+DVF:J3I4 -VN7X
M81[G3/C6K ESEZVSGDY5P425M7=36(FH12QXW\XSM%(*\(-#O\1?I@J1ML T
M+310&F1]!AVA*;("Q8H4088HK!.;:TY-T5Z)@YY-C T83KLM3J041\<P4KCG
M\V N>@?[Z:UJ2<PMVCFF-.28&J0!,P?!Y9P831.D$K)-]%0!G_(>9<:;!=H2
MFK1?:-!;Z[2S85.EXHF,;HC/"T2AEI(??H,K2A#.$EHN."8A,5]3J#:SZPP+
M<3UH2AV0T,-P. L=A<Q'=V_,+W/7DOV$V%.**_FSS&:XM\VB<:X0E 1[ML.
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M5 9)]< YAFA%>^V#X!VB7E^)'TZOGS-AEZ^OW1]N'G9E2Y6ZXVT1KQYQ=E"
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MKQ>4WM0V]&FG/)N+<-=X:@T'UXX$2UN.(>WF9]@Z#,K.#M&+ESOJ44D>S+7
M=+V5[[8S\MN]TL&]]$K!4D&!H>U1R8+V67Z\Z_,=&N/W_]?UF;A6U,;VU:NS
MSTV+RFBS^7IN4KGKQPP_%2V])_N/]\3C\>%@__CXZ#,30S_5QN[_YS+2!5F^
MWQ0XW8]H\COW$[C?\4_O_C]02P,$%     @ &T:N7$A.AI3P#P  C7(  !$
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MU4LMB[0SI<;(L> WK$Q.N4@D.0VB2+PEU_>1=&G#G^?B*KJ=FIF-4JL;C>2
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M$>,1] / #"=Y63\*8'!LA[L31T,_:;X,)(OQ>!F1KQ!0;3B-30.J%C2J/DO
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M5+DS5+==8ANQ7>H'W,7L1.&!T__9)F4)V22?S^^RIR-2T>B[10I)$TN71T-
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M96$N:'1M4$L! A0#%     @ &T:N7-C!N1P6&@  @7<  !\
M ( !P!\  &5X.3DR<VYT:69D86UE971I;F<R,#(V,#4Q-"YH=&U02P$"% ,4
M    "  ;1JY<2$Z&E/ /  "-<@  $0              @ $3.@  <VYT:2TR
M,#(V,#4Q-"YH=&U02P$"% ,4    "  ;1JY<BC[&I5\"  #Y!@  $0
M        @ $R2@  <VYT:2TR,#(V,#4Q-"YX<V102P$"% ,4    "  ;1JY<
M-8LBU(8)   "6   %0              @ ' 3   <VYT:2TR,#(V,#4Q-%]L
M86(N>&UL4$L! A0#%     @ &T:N7-F'\*<+!@  ]3(  !4
M ( !>58  '-N=&DM,C R-C U,31?<')E+GAM;%!+!08     !@ & )T!  "W
%7      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>snti-20260514_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="snti-20260514.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
        </entity>
        <period>
            <startDate>2026-05-14</startDate>
            <endDate>2026-05-14</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-22">0001854270</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-23">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2026-05-14</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">SENTI BIOSCIENCES HOLDINGS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-40440</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">42-1912154</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">2 Corporate Drive, First Floor</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">239-2030</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">SNTI</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="c-1" id="f-21">true</dei:EntityExTransitionPeriod>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-24">2026-05-14</dei:DocumentPeriodEndDate>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-25">2026-05-14</dei:DocumentPeriodEndDate>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
